Skip to Main Content

NISH (NITAG Support Hub) 13: Typhoid Conjugate Vaccine (TCV) : WHO Position Paper 2018

This Library Guide is a collection of useful documents & evidence on the safety, efficacy, effectiveness and impact of the Typhoid Conjugate Vaccine (TCV) to support NITAG members and other policy makers throughout Africa with making evidence-based recom

WHO Position paper of 30 March 2018

WHO Position Paper of 20 March 2018

References from the Typhoid Position Paper

WHO. Expert Committee on Biological Standardization. Sixty-fourth report. WHO technical report series; no. 987. 2013. Available at http://apps.who.int/iris/ bitstream/handle/10665/129494/TRS_987_eng.pdf

Mohan VK et al. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61:393–402.https://doi.org/10.1093/cid/civ295

Jin C et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390:2472–2480.https://www.thelancet.com/action/showPdf?pii=S0140-6736%2817%2932149-9

Lanh, M. N., Van Bay, P., Ho, V. A., Thanh, T. C., Lin, F. Y. C., Bryla, D. A., ... & Szu, S. C. (2003). Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New England Journal of Medicine, 349(14), 1390-1391. DOI: 10.1056/NEJM200310023491423

Voysey, M., & Pollard, A. J. (2018). Seroefficacy of Vi polysaccharide–tetanus toxoid typhoid conjugate vaccine (Typbar TCV). Clinical Infectious Diseases, 67(1), 18-24.doi.org/10.1093/cid/cix1145

 Darton TC et al. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Negl Trop Dis. 2016;10:e0004926. https://doi.org/10.1371/journal.pntd.0004926

Antillon M et al. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017;35:3506–3514.https://doi.org/10.1016/j.vaccine.2017.05.001

Lo NC et al. Comparison of strategies and incidence thresholds for Vi conjugate vaccines against typhoid fever: A cost- effectiveness modeling study. J Infect Dis. 2018;https://doi.org/10.1093/infdis/jix598

World Health Organization. (2018). Typhoid and other invasive salmonellosis. Vaccine preventable diseases surveillance standards. Geneva, Switzerland, 1-13.https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/vpd-surveillance-standards-publication/who-surveillancevaccinepreventable-21-typhoid-r2.pdf?sfvrsn=993904a6_10&download=true